Whole Foods Market Recalls Pre-packaged Mini Caesar And Mini Mesclun Goat Cheese Salad In Three States, Due To Undeclared Allergen

Whole Foods Market is recalling mini 4oz. containers of pre-packaged Caesar salad and Mesclun Goat Cheese salad sold in stores on July 8,, 2014 throughout New York, New Jersey (Excluding Princeton, Cherry Hill and Marlton) and Connecticut (Excluding Glastonbury, West Hartford and Bishop’s Corner) due to mislabeling and a resulting undeclared allergen of fish and egg (Caesar) and tree nuts (Mesclun Goat Cheese). The product has a Sell by date of: 7/11/14.

FDA seeks permanent injunction against California pharmaceutical company

On June 25, the U.S. Department of Justice, at the request of the U.S. Food and Drug Administration, filed a complaint for permanent injunction in the U.S. District Court for the Central District of California against Laclede, Inc. (Laclede) of Rancho Dominguez, California, and its president, Michael A. Pellico. The complaint claims that Laclede illegally distributes over-the-counter vaginal drug products without required FDA approval.

Flowers Foods Issues Allergy Alert and Voluntary Recall on Limited Quantity of Sunbeam, Bunny, Flowers Deli, and Ingles Bar-B-Q Bread Sold in Alabama, Georgia, Louisiana, and Tennessee

Flowers Foods (NYSE: FLO) is voluntarily recalling the following brands of Bar-B-Q bread because they may contain undeclared milk. People who have allergies to dairy products run the risk of serious or life-threatening allergic reaction if they consume these products. No illnesses have been reported to date.
Read The Complete Story!

FDA outlines expectations for human drug compounders, including registered outsourcing facilities

Today, the U.S. Food and Drug Administration issued several policy documents regarding compounded drug products for human use, as part of the agency’s continuing effort to implement the compounding provisions of the Drug Quality and Security Act (DQSA), enacted in November 2013. The policy documents consist of a draft interim guidance, a proposed rule, a final guidance, and two revised requests for nominations for the bulk drug substances lists.